Why I'm Downgrading Berkshire Hathaway After A Strong-Looking Quarter

Berkshire’s Q2 operating earnings rose 16.3%, but the article flags weaker underlying growth of 5.2% excluding FX gains and a deterioration in insurance performance, with GEICO’s combined ratio worsening to 91.2%. The firm is accelerating capital deployment, investing $26B in H1 2026 and resuming buybacks, but the cash pile remains large at $365.5B, making meaningful reductions difficult at the current scale. Despite the strong-looking quarter, the author downgrades to Hold with a $470–480/share target (~1.35x book), citing insurance headwinds and shares trading around 1.50x book.

Analysis

BRK is still a high-quality franchise, but the incremental return on incremental capital is slipping. With short rates elevated, the cash pile is no longer dead money; that reduces the urgency to force deployment and makes the market less likely to pay up for "dry powder" alone. The real valuation pressure comes from paying a premium multiple for a business where buybacks only matter if they are done at a meaningful discount to intrinsic value; otherwise they mostly offset dilution in sentiment rather than create obvious per-share accretion.

The bigger second-order risk is that insurance softness becomes the narrative anchor. When investors start treating BRK as a quasi-bond proxy, small underwriting deterioration can compress the premium quickly, while cleaner financials with more explicit capital return can attract relative inflows. Over the next 1-3 months, the key catalyst is whether deployment runs at a pace that credibly changes the cash balance trajectory; over 6-18 months, the question is whether Greg Abel can sustain Buffett-era capital allocation discipline without the market paying the old scarcity premium. A move back toward the implied fair-value band would be more likely if underwriting improves, capital deployment accelerates above roughly $35B annualized, or a market drawdown makes the cash optionality more valuable than today.

Contrarian view: the consensus may be overreacting to the cash headline and underestimating the earnings power of a large, high-yielding liquidity pool in a 4-5% rate world. That makes an outright short unattractive. The better expression is relative underweight versus other financials until insurance trends and buyback intensity prove they can offset the valuation premium.

Key Decisions for Investors

• Underweight BRK.B vs SPY for the next 1-3 months; use any strength toward ~1.5x book to add the relative short. Falsify if annualized capital deployment exceeds $35B or insurance margins re-accelerate.
• Pair trade: long CB / short BRK.B on a 3-6 month horizon to express cleaner underwriting and clearer capital-return visibility versus a conglomerate where buybacks are less accretive at the current multiple.
• For existing BRK.B holders, sell 6-9 month covered calls 10-15% out of the money into rallies; the stock likely trades in a range unless there is either a valuation reset or a materially stronger capital deployment cadence.
• Set an alert rather than a trade: if GEICO-style combined ratios stay above 90 or worsen again next quarter, the market is likely to re-rate BRK.B lower faster than earnings alone would suggest.